Date Time Partnership launched to fast track drug discovery The University of Nottingham is part of a new industry collaboration launched to accelerate drug discovery projects that will fast track research from lab to patient. The University of Nottingham is one of four universities selected by drug development company Evotec SE and global pharmaceutical company Bristol Myers Squibb to be part of the newly formed beLAB1407. Evotec, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Nottingham, Birmingham, Edinburgh and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.